( MENAFN - GlobeNewsWire - Nasdaq) PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the“Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapyTM, announced that it has contributed two scientific abstracts that have been accepted for presentation at SLEEP 2024 , a joint meeting of the American Academy of Sleep medicine and the Sleep Research Society, June 1-5 in Houston, TX.
This study evaluated the clinical performance of a novel, precision oral appliance therapy (ProSomnus OAT) medical device made entirely from a US Pharmacopeia (USP) medical grade class VI qualified material for the treatment of OSA. Data from 91 patients with OSA found that 98% of patients with mild and moderate OSA were successfully treated to an AHI < 10 events per hour. No patients discontinued treatment due to material-related side effects.
The results of the study show that a precision ProSomnus OAT device made from USP Class VI qualified material is safe and efficacious for the treatment of OSA. Review of post-market surveillance surveys collected from 10,880 patients and 646 providers over a 60-month period showed that 98% of patients and providers reported a 'first time fit', indicating a high-quality device made precisely to specification. 99% of patients reported being satisfied with their appliance and 98% of providers reported being satisfied with the device upon delivery to the patient.
These results indicate that ProSomnus precision OAT devices are asso.